Aktiesnakken — Juni 2013
-
Kaplan Meier kurven ser flot ud for Tacro
-
ifht. prograf
-
Luxymia
godkendt i Japan -
Sådan
-
Q&A nu for Velo
-
Bowers
-
-
Polvino svarer flot på bowers spørgsmål, men jeg forstår ærligt talt ikke meget af det
-
Zealand skal nok ned med 5-10% i dag på Japan godkendelsen
-
De siger at uptake i salget for LCP-Tacro vil være rapidly
-
det var at organfrastødelsen var højere i dette studie end i både phase II og switch.
-
Men at det gældte for begge arme
-
så han ville vide om det havde noget med pretreatment at gøre
-
Polvino siger nu at for 10 år siden var organfrastødelse omkring 50%
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind